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High mortality in subjects with both diabetes and HIV in sub-Saharan Africa
Smit et al. [1] report that the mean age of people living
with HIV in sub-Saharan Africa is increasing; the
proportion suffering from at least one noncommunicable
disease is predicted to rise. The authors are correct to
highlight this important demographic change. There is a
scarcity of data on the interaction between HIV and
noncommunicable diseases. We performed the first
prospective cohort study of diabetic retinopathy in
sub-Saharan Africa [2,3]. In patients with both diabetes
and HIV infection, we found a very high mortality rate
but no increase in the rate of diabetic microvascular
complications. Participants were systematically sampled
from two hospital-based, primary care diabetes clinics.
Glycaemic control, SBP, HIV status, urine albumin–
creatinine ratio, and haemoglobin and serum lipid levels
were assessed at baseline, 12 and 24 months. Retinopathy
was graded at an accredited reading centre. Mortality was
confirmed systematically either by death certificate or by
key informants.
Of 357 people with diabetes included in the study, 50
were HIV positive (48 at baseline and two new diagnoses
during the study). At baseline, HIV-positive participants
demonstrated lower mean age (48.2 vs. 53.3 years;
P¼ 0.015) and shorter duration of diabetes (2.8 vs. 4.4
years; P¼ 0.002) than HIV-negative individuals; a higher
proportion of HIV-positive participants demonstrated
raised urine albumin–creatinine ratio (50.0 vs. 31.6%;
P¼ 0.015). Of 41 HIV-positive participants who under-
went annual CD4þ cell count testing, 32 (78%), 25 (61%)
and 14 (34%) individuals had a CD4þ cell count below
500, 350 and 200 cells/ml at any visit, respectively. At 24
months, 38 participants were assessed and nine had died
(94% follow-up). Cumulative incidence of death amongst
HIV-positive participants with diabetes at 12 and 24
months was 10% (1.7–18.3) and 18.1% (7.4–28.8),
respectively (n¼ 50), compared with 5.4% at 24 months
[2.8–8.0, 95% confidence interval (CI); n¼ 294] in HIV-
negative participants with diabetes. In comparison,
Malawi National HIV Programme data indicate a
mortality rate of 5.1% 24 months after commencement
of antiretroviral therapy [4]. In univariate analysis, death
during the study was associated with proliferative diabetic
retinopathy [odds ratio (OR) 6.47; 2.51–16.7;
P¼ 0.0001], moderate visual impairment (OR 8.21;
2.48–27.1; P¼ 0.001) and HIV (OR 3.72; 1.54–9.00;
P¼ 0.003).
At 24 months, two-step (or greater) progression of
diabetic retinopathy was observed in 2/38 HIV-positive
participants (5.3%) compared with 55/251 (21.9%) HIV-
negative participants (P< 0.015 Fisher’s exact). In multi-
variate logistic analysis, two-step progression of diabetic
retinopathywas associatedwithHbA1c (OR1.27, 95%CI
1.12–1.45), baseline grade of retinopathy (OR 1.39, 95%
CI 1.02–1.91) and HIV infection (OR 0.16, 95% CI
0.03–0.78). The negative association between retinopathy
progression and HIV infection may have been strongly
influenced by the high mortality rate in people with HIV
(people whose retinopathy would have otherwise pro-
gressed). No trend towards worsening renal function was
identified at 24 months. Our data suggest that mortality in
patients with both diabetes and HIV infection in Southern
Malawi is very high. Previous studies have indicated that
both HIV infection and antiretroviral therapies are
associatedwith a vasculopathywhichmanifests as increased
cardiovascular and cerebrovascular risk [5,6]. We did not
find an increased rate of diabetic microvascular complica-
tions in personswithHIV in our cohort. Our results add to
the growing literature on interaction between HIV and
noncommunicable disease and highlight the urgent need
for provision of integrated services for patients with
diabetes and HIV infection.
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First reported use of zidovudine for prevention of perinatal HIV transmission in a premature neonate on
extra corporal membrane oxygenation
The effects of extra corporal membrane oxygenation
(ECMO) on pharmacokinetics of drugs is difficult to
predict. Generally, an increased volume of distribution,
decreased drug elimination, and sequestration of the drug
to the ECMO circuit are factors potentially influencing
the pharmacokinetics of drugs during ECMO [1,2].
Zidovudine is the only antiretroviral agent suitable for
intravenous (IV) use in newborns for the prevention of
perinatal HIV transmission. No reported cases of the
influence of ECMO on the pharmacokinetics of
zidovudine in prematures were found. We describe the
first pharmacokinetics data in a premature neonate
requiring IV zidovudine while on ECMO.
A premature child (gestational age 32 weeks) born from a
virologically suppressed HIV-infected mother required
ECMO to undergo the resection of an intrathoracic
lesion compromising the lungs. IV zidovudine was
administered for the prevention of HIV transmission as
per standard guidelines. To cope with the anticipated
increased volume of distribution (Vd) and to avoid the
risks caused by under treatment, IV zidovudine was dosed
9mg/kg/day (150% of the dose normally used in
premature infants) for the duration of ECMO. Plasma
samples were taken before, during and after ECMO.
Samples were analysed using liquid chromatography-
tandem mass spectrometry technology. Therapeutic drug
monitoring (TDM) was used to observe treatment and
pharmacokinetics parameters were calculated using
noncompartmental analysis in Phoenix WinNonlin
(Certara USA, Inc., Princeton, New Jersey, USA).
Parents consented to the presentation of these data.
With clearance 0.62 l/h, Vd 3.3 l, and t1/2 of 3.6 h,
zidovudine concentrations remained above 0.8mg/l
during ECMO (Fig. 1). While pharmacokinetic reports
on prematures are highly variable with no Ctrough or area
under the curve values being reported, these pharmaco-
kinetics parameters suggest slow clearance of zidovudine,
leading to a degree of exposure that has been correlated to
increased safety risks in earlier studies [3]. No adverse
events were reported in this case and zidovudine levels
returned to normal on standard doses after ECMO
cessation [4,5]. The HIV proviral DNA PCR in the child
was negative at 3 months of age.
It might be difficult to tease out the influence of ECMO
versus the premature age on the pharmacokinetics of
zidovudine in this particular child. However, the fact that,
after ECMO pharmacokinetics parameters of zidovudine
were normal after administering normal doses while
they were higher during ECMO at a higher dose of
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Fig. 1. Zidovudine levels post dosing. * Zidovudine levels
with intravenous medication, no extra corporal membrane
oxygenation. & Zidovudine levels with IV medication on
extra corporal membrane oxygenation. AZT, zidovudine.
